Palvella Therapeutics, Inc. (PVLA) · Oct 28, 2026 · Other events

Palvella FDA review sets February 2027 decision for QTORIN

FDA Priority Review — PDUFA target action date: February 28, 2027

Palvella’s FDA acceptance and priority review for QTORIN rapamycin move its lead therapy into the final regulatory stretch ahead of a 2027 decision.

Palvella is a late-clinical-stage rare-disease biotech moving QTORIN rapamycin from completed rolling NDA submission toward a potential standalone U.S. launch in the first half of 2027; the company had already disclosed that submission and launch preparation were underway.

The regulatory path is now materially de-risked, but approval is not yet secured. The FDA accepted the NDA for filing and granted Priority Review, assigning a February 28, 2027 PDUFA target action date. 〔0〕 This is more than a routine submission acknowledgment: it establishes a defined, accelerated review timetable for Palvella’s lead program.

The filing strengthens the launch story because the product could address an untreated rare disease with no approved therapy. Palvella says QTORIN rapamycin could become the first FDA-approved treatment for microcystic lymphatic malformations, while its Phase 3 SELVA study showed improvement on the primary endpoint in 95% of evaluable participants aged 6 and older. 〔1〕 The application also reports no drug-related serious adverse events and low systemic rapamycin concentrations in SELVA. 〔2〕

The surprise is the formal FDA validation and timing, not the general direction. Palvella had already completed the rolling submission and was preparing for a potential first-half-2027 launch, so the filing confirms an expected regulatory progression rather than creating a new development path. The added Priority Review designation and precise PDUFA date are the meaningful incremental information; there is no earnings-style consensus benchmark for this event.

Bottom line: Palvella has moved QTORIN rapamycin into a defined, accelerated FDA review with a February 28, 2027 decision date. The business story advances from late-stage development to imminent regulatory and commercial execution, although the key approval risk remains.

What to watch next

FDA decision on QTORIN rapamycin, February 28, 2027

Original filing on SEC EDGAR

More Palvella Therapeutics, Inc. news

• Palvella earnings beat as launch prep drives a wider loss